Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2021 08:11 ET | Source: Silo Pharma, Inc.

Silo Pharma achieves milestone - Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

Englewood Cliffs NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
August 25, 2021 08:01 ET | Source: Silo Pharma, Inc.

Silo Pharma Advances Psychedelic Patent Portfolio

Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
August 11, 2021 08:10 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research

Englewood Cliffs NJ, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
July 27, 2021 08:08 ET | Source: Silo Pharma, Inc.

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin Englewood Cliffs NJ, July 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a...
July 21, 2021 10:42 ET | Source: Silo Pharma, Inc.

Silo Pharma To Appear On National Media Broadcast on Psychedelics

Englewood Cliffs, NJ , July 21, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has...
July 12, 2021 08:08 ET | Source: Silo Pharma, Inc.

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

Englewood Cliffs NJ, July 12, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research...
July 07, 2021 08:15 ET | Source: Silo Pharma, Inc.

Silo Pharma extends agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide

Englewood Cliffs NJ, July 07, 2021 (GLOBE NEWSWIRE) -- Silo and University of Maryland, Baltimore extend Option agreement Rheumatoid arthritis (RA) is a chronic disease in which autoimmune attack...
June 08, 2021 08:15 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased...
May 25, 2021 08:15 ET | Source: Silo Pharma, Inc.

Silo Pharma Submits Application for NASDAQ up-listing

Englewood Cliffs, NJ, May 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased...
May 13, 2021 08:15 ET | Source: Silo Pharma, Inc.

Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right